Innovation Beyond Tech: AI and Policy Shifts Drive Healthcare Sector Growth

The healthcare sector is emerging as a significant area for artificial intelligence integration, offering a low-correlation alternative to the technology market. Driven by an aging population and a 55-fold increase in AI-enabled medical device authorizations over the last decade, the sector is seeing improved earnings fundamentals and clearing regulatory hurdles. For the health insurance technology market, these advancements in diagnostics, managed care, and data-driven clinical decision support signal a shift toward more efficient, personalized care delivery and drug development.

The healthcare sector has reached a turning point in AI adoption, supported by significant regulatory shifts and technological progress. The FDA has recently allowed computer-based alternatives to animal testing and reduced oversight for lab-developed tests, providing diagnostic companies with greater flexibility. Furthermore, a Department of Energy initiative aims to build a unified AI platform using data from 17 federal labs to accelerate biotech breakthroughs. These changes have led to a dramatic surge in AI-enabled medical device authorizations, which grew from just six in 2015 to 331 in 2025. Radiology and diagnostics represent 77% of these clearances, highlighting AI's critical role in pattern recognition and clinical decision support.

From a market perspective, healthcare is demonstrating resilience as a defensive sector with strong fundamentals. In 2025, 89% of healthcare companies in the S&P 500 exceeded earnings expectations, and analysts project an acceleration in growth for managed care and pharmaceuticals by 2027. This growth is underpinned by structural forces, specifically an aging population where 20% of the U.S. will be over 65 by 2030. This demographic spends two to three times more on healthcare than younger cohorts, ensuring long-term demand for health insurance services and equipment.

Despite its innovative edge, the healthcare sector currently trades at a 16% valuation discount to the broader market, largely due to past policy headwinds like the One Big Beautiful Bill Act (OBBBA) and the Most Favored Nation (MFN) drug pricing rule. However, these policy clouds are clearing in 2026 as companies secure manufacturing exemptions and 17 major pharmaceutical firms reach pricing agreements with the administration. For the health insurance technology sector, the integration of AI into diagnostic platforms and partnerships between pharma and specialized firms using genomic datasets are expected to make care more personalized and drug development more efficient, potentially closing the valuation gap as the market recognizes the impact of AI on human health.